SMARCB1-deficient malignant neoplasm of the pancreas with heterogeneous morphologies that cannot be classified into existing histologic types.

IF 2.5 4区 医学 Q2 PATHOLOGY
Pathology International Pub Date : 2024-12-01 Epub Date: 2024-10-28 DOI:10.1111/pin.13489
Yusuke Kouchi, Nozomu Sakai, Sakurako Harada-Kagitani, Ryotaro Eto, Takashi Mishima, Shigetsugu Takano, Katsuhiro Nasu, Jun-Ichiro Ikeda, Masayuki Ohtsuka, Takashi Kishimoto
{"title":"SMARCB1-deficient malignant neoplasm of the pancreas with heterogeneous morphologies that cannot be classified into existing histologic types.","authors":"Yusuke Kouchi, Nozomu Sakai, Sakurako Harada-Kagitani, Ryotaro Eto, Takashi Mishima, Shigetsugu Takano, Katsuhiro Nasu, Jun-Ichiro Ikeda, Masayuki Ohtsuka, Takashi Kishimoto","doi":"10.1111/pin.13489","DOIUrl":null,"url":null,"abstract":"<p><p>A 50-year-old male with a pancreatic tail tumor underwent distal pancreatectomy. At 14 and 27 months after the primary surgery, metachronous liver metastases were identified and partial hepatectomies were performed for each. Pathologic findings of the primary pancreatic tumor were heterogeneous, but they essentially categorized into two components based on their cytologic features: (i) clear cell component and (ii) epithelioid cell component. The metastatic hepatic tumor was entirely composed of the epithelioid cell component. SMARCB1 expression was lost by immunohistochemistry and heterozygous deletion of SMARCB1 was identified by fluorescence in situ hybridization for both the primary and metastatic tumors. Targeted DNA sequencing of a metastatic hepatic tumor sample was performed and SMARCB1 loss was identified. Based on the morphologic, immunohistochemical, and molecular analyzes, the present case was difficult to classify into any of the existing entities. SMARCB1 deficiency might play a key role in the tumorigenesis.</p>","PeriodicalId":19806,"journal":{"name":"Pathology International","volume":" ","pages":"691-696"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pin.13489","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

A 50-year-old male with a pancreatic tail tumor underwent distal pancreatectomy. At 14 and 27 months after the primary surgery, metachronous liver metastases were identified and partial hepatectomies were performed for each. Pathologic findings of the primary pancreatic tumor were heterogeneous, but they essentially categorized into two components based on their cytologic features: (i) clear cell component and (ii) epithelioid cell component. The metastatic hepatic tumor was entirely composed of the epithelioid cell component. SMARCB1 expression was lost by immunohistochemistry and heterozygous deletion of SMARCB1 was identified by fluorescence in situ hybridization for both the primary and metastatic tumors. Targeted DNA sequencing of a metastatic hepatic tumor sample was performed and SMARCB1 loss was identified. Based on the morphologic, immunohistochemical, and molecular analyzes, the present case was difficult to classify into any of the existing entities. SMARCB1 deficiency might play a key role in the tumorigenesis.

SMARCB1缺陷型胰腺恶性肿瘤,形态不一,无法归入现有组织学类型。
一名患有胰尾肿瘤的 50 岁男性接受了胰腺远端切除术。在原发手术后 14 个月和 27 个月,发现了并发的肝转移瘤,并分别进行了肝部分切除术。原发性胰腺肿瘤的病理结果各不相同,但根据细胞学特征,基本上可分为两类:(i) 透明细胞成分和 (ii) 上皮样细胞成分。转移性肝肿瘤完全由上皮样细胞组成。免疫组织化学检测发现,原发性肿瘤和转移性肿瘤都失去了SMARCB1的表达,荧光原位杂交也发现了SMARCB1的杂合性缺失。对转移性肝肿瘤样本进行了DNA靶向测序,发现了SMARCB1缺失。根据形态学、免疫组化和分子分析,本病例难以归入任何现有实体。SMARCB1缺失可能在肿瘤发生中起着关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pathology International
Pathology International 医学-病理学
CiteScore
4.50
自引率
4.50%
发文量
102
审稿时长
12 months
期刊介绍: Pathology International is the official English journal of the Japanese Society of Pathology, publishing articles of excellence in human and experimental pathology. The Journal focuses on the morphological study of the disease process and/or mechanisms. For human pathology, morphological investigation receives priority but manuscripts describing the result of any ancillary methods (cellular, chemical, immunological and molecular biological) that complement the morphology are accepted. Manuscript on experimental pathology that approach pathologenesis or mechanisms of disease processes are expected to report on the data obtained from models using cellular, biochemical, molecular biological, animal, immunological or other methods in conjunction with morphology. Manuscripts that report data on laboratory medicine (clinical pathology) without significant morphological contribution are not accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信